茵冠生物紧密围绕我国细胞治疗“双轨制”监管特点，以创新生物药申报为主战略，同时与国内顶尖三甲医院合作落地生物医药新技术临床研究项目。公司已与全国80余家三甲医院建立长期战略合作，在神经系统疾病、退行性疾病等重点领域，积累了覆盖40余个单病种的临床方案与丰富的研究经验，累计案例达数万例。目前5项临床研究项目正在开展，并承担“十四五”和“十五五”国家重大专项研发课题。

Based on its extensive R&D and clinical experience, Inglos Biotech provides partner hospitals with support from R&D and preparation to clinical research, aiming to ensure the scientific and efficient nature of clinical research and accelerate the transformation and application of research results.